GlassScriptPhysician profile
Amena Fatima Mohiuddin
NPI 1144726308
$988.66
in general payments reported to CMS, 2019-2025
29 companies · $524 in 2025
The $524 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $465 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973 · Education: $15.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.41 |
| Education | $15.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $132.26 | 2024 | Libtayo |
| Beone Medicines USA, INC. | $59.02 | 2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $55.71 | 2024 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $50.30 | 2024-2025 | |
| Taiho Oncology, INC. | $47.60 | 2024 | |
| Genzyme Corporation | $47.58 | 2024-2025 | |
| Caris Mpi, INC. | $44.79 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $41.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $40.72 | 2025 | Calquence |
| Puma Biotechnology, INC. | $40.62 | 2024 | |
| Myriad Genetic Laboratories, INC. | $37.87 | 2025 | Myrisk |
| Janssen Pharmaceuticals, INC | $37.48 | 2024 | Xarelto |
| Abbvie INC. | $30.40 | 2025 | |
| Novocure INC. | $30.38 | 2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $26.60 | 2024 | Ayvakit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.41 | 2024 | Enhertu |
| Genmab U.S., INC. | $23.05 | 2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $22.69 | 2025 | Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $21.44 | 2024 | Augtyro |
| Pharmacosmos Therapeutics INC. | $19.77 | 2025 | Monoferric |
| Janssen Biotech, INC. | $19.13 | 2025 | Darzalex, Talvey |
| Ipsen Biopharmaceuticals, INC | $18.93 | 2025 | Onivyde |
| Eisai INC. | $17.61 | 2025 | |
| Pfizer INC. | $17.56 | 2025 | |
| Stemline Therapeutics INC. | $16.95 | 2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $15.95 | 2025 | Tgct, Qinlock |
| Astellas Pharma US INC | $15.65 | 2025 | Padcev |
| Amneal Pharmaceuticals LLC | $15.34 | 2025 | Alymsys |
| Glaxosmithkline, LLC. | $15.25 | 2025 | Ojjaara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amena Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.